valsartan has been researched along with Hypertrophy, Left Ventricular in 58 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (12.07) | 18.2507 |
| 2000's | 28 (48.28) | 29.6817 |
| 2010's | 19 (32.76) | 24.3611 |
| 2020's | 4 (6.90) | 2.80 |
| Authors | Studies |
|---|---|
| Ageev, FT; Ovchinnikov, AG | 1 |
| Heimark, S; Julius, S; Kjeldsen, SE; Larstorp, AC; Liestøl, K; Mancia, G; Mariampillai, JE; Mehlum, MH; Rostrup, M; Søraas, CL; Wachtell, K; Weber, MA | 1 |
| Axelsson Raja, A; Bach, RG; Becker, JR; Benson, L; Bundgaard, H; Canter, C; Cirino, AL; Colan, SD; Day, SM; Ho, CY; Lakdawala, NK; Lever, HM; MacRae, CA; Margossian, R; McMurray, JJV; Mestroni, L; Murphy, AM; Orav, EJ; Owens, AT; Patel, AR; Pereira, AC; Rossano, JW; Russell, MW; Seidman, CE; Solomon, SD; Soslow, JH; Taylor, MRG; Thrush, P; Vissing, CR; Wheeler, MT; Wilmot, I; Zahka, K | 1 |
| Jin, Q; Li, X; Wang, L; Wang, Q; Zhang, Q; Zheng, Y; Zhu, Q | 1 |
| Braunwald, E; Cirino, AL; Colan, SD; Day, SM; Desai, AS; Ho, CY; Lipshultz, SE; MacRae, CA; McMurray, JJV; Orav, EJ; Shi, L; Solomon, SD | 1 |
| Aichner, S; Albrecht, D; Bremerich, J; Delles, C; Freyhardt, P; Heye, T; Hrabak-Paar, M; Janka, R; Keicher, C; Khder, Y; Langenickel, T; Mayr, M; Ott, C; Schmieder, RE; Wagner, F; Yates, D | 1 |
| Akagi, S; Ito, H; Kondo, M; Miura, D; Miyoshi, T; Nakamura, K; Ohno, Y; Saito, Y; Yoshida, M | 1 |
| Li, N; Ma, R; Yu, J; Yu, X; Zhao, X; Zhao, Y | 1 |
| Aydoğdu, A; Azal, Ö; Baysan, O; Deniz, F; Meriç, C; Sağlam, K; Serdar, M; Taşçı, İ | 1 |
| Chen, G; He, QY; Pan, SF; Pan, SQ; Shen, C; Zhang, XM | 1 |
| Chang, F; Gui-Yi, Y; Mao-Huan, L; Shu-Xian, Z; Wei, W; Zhi-Bin, H | 1 |
| Harada, E; Hattori, T; Matsuura, N; Murohara, T; Nagasawa, K; Nagata, K; Niinuma, K; Takahashi, K; Takatsu, M; Watanabe, S | 1 |
| Greenwood, JP; Negrou, K; Oliver, JJ; Plein, S; Ripley, DP; Struthers, AD; Worthy, G | 1 |
| Xu, C; Xu, J; Zhao, L | 1 |
| Bai, F; Chang, P; Li, X; Lin, X; Wang, Q; Xu, H; Yang, M; Yu, J; Zhang, X; Zhang, Z; Zhao, F; Zhao, X | 1 |
| Imaizumi, T; Kai, H; Kuwahara, F; Mizoguchi, M; Mizuta, Y; Nakaura, H; Osada, K; Tahara, N | 1 |
| Bader, M; Carretero, OA; Rhaleb, NE; Shesely, EG; Xu, J; Yang, JJ; Yang, XP | 1 |
| Arnold, JM; Bourgoun, M; Califf, RM; Ghali, JK; Kober, L; McMurray, JJ; Meris, A; Pfeffer, MA; Skali, H; Solomon, SD; Velazquez, EJ; Verma, A | 1 |
| Inoue, M; Iwano, H; Kaga, S; Komatsu, H; Matsuno, K; Mikami, T; Nishida, M; Okada, M; Onozuka, H; Shimizu, C; Tsutsui, H; Yamada, S; Yokoyama, S | 1 |
| Divchev, D; Grothusen, A; Luchtefeld, M; Schieffer, B | 1 |
| Bellocci, F; Crea, F; Giubilato, G; Ierardi, C; Pieroni, M; Santangeli, P; Vitulano, N | 1 |
| Gong, C; Huang, JF; Huang, SL; Jiang, XJ; Luo, M; Zhang, ZF; Zhao, Y | 1 |
| Kimura, S; Matsubara, H; Sawada, T; Shiraishi, J; Yamada, H | 1 |
| Bains, J; Smith, WB | 1 |
| Hasegawa, H; Kobayashi, Y; Komuro, I; Kuwabara, Y; Mizuma, H; Narumi, H; Shindo, S; Takano, H | 1 |
| Gurbuz, S; Kucukler, N; Kurt, IH; Topaloglu, C; Yalcin, F | 1 |
| Ebina, T; Hibi, K; Kimura, K; Kosuge, M; Kusama, I; Morita, S; Nozawa, N; Okuda, J; Ozaki, H; Tsukahara, K; Umemura, S; Yano, H | 1 |
| Derosa, G; Fogari, R; Maffioli, P; Mugellini, A; Preti, P; Zoppi, A | 1 |
| Krum, H; Martin, J | 1 |
| Bedigian, MP; Falk, SA; Gengaro, PE; Gurevich, AK; Nemenoff, RA; Rizeq, M; Schrier, RW; Summer, SN; Weinberger, HD | 1 |
| deBlois, D; Der Sarkissian, S; Duguay, D; Hamet, P; Marchand, EL | 1 |
| Kanno, Y; Nakamoto, H; Okada, H; Sugahara, S; Suzuki, H | 1 |
| Aizawa, Y; Kamimura, T; Kato, K; Soda, S; Suzuki, K | 1 |
| Asada, A; Maeda, K; Nakamura, M; Watanabe, T; Yasunari, K; Yoshikawa, J | 1 |
| Fu, H; Li, Y; Lu, Z; Ma, Y; Xiao, J | 1 |
| Anan, F; Hara, M; Nakagawa, M; Ooie, T; Saikawa, T; Takahashi, N; Yonemochi, H; Yoshimatsu, H; Yufu, K | 1 |
| Anavekar, NS; Arnold, JM; Barvik, S; Bourgoun, M; Califf, RM; Ghali, JK; Khrakovskaya, M; McMurray, JV; Pfeffer, MA; Schwartz, Y; Skali, H; Solomon, SD; Velazquez, EJ; Warnica, JW | 1 |
| Laverty, R; Ledingham, JM | 1 |
| Dahlöf, B | 1 |
| Birkenhäger, WH; Hansen, TW; Staessen, JA | 1 |
| Abu-Hijleh, M; Garadah, T; Golbahar, J; Gumaa, K; Kassab, S; Senok, S; Wazir, J | 1 |
| Fujiwara, H; Hukunishi, M; Ito, Y; Kakami, M; Kawasaki, M; Matsuno, Y; Minatoguchi, S; Miyajima, K; Nishigaki, K; Takemura, G | 1 |
| Ahmed, A; Husain, A; Perry, GJ | 1 |
| Arnold, JM; Aurigemma, GP; Bourgoun, M; Daley, WL; Fields, H; Hippler, SE; Janardhanan, R; Lacourcière, Y; Mulvagh, SL; Naqvi, TZ; Purkayastha, D; Solomon, SD; Thomas, JD; Verma, A; Zile, MR | 1 |
| Julius, S; Mann, J | 1 |
| Harder, S; Kenedi, P; Rietbrock, N; Schmidt, A; Thürmann, PA | 1 |
| Thürmann, PA | 2 |
| Balaev, VV; Drozdova, GA; Frolov, VA; Mustiatsa, VF; Rieger, P | 1 |
| Balaev, VV; Drozdova, GA; Frolov, VA; Mustiatsa, VF | 1 |
| Gottdiener, JS | 1 |
| Devereux, RB | 1 |
| Ahonen, J; Finckenberg, P; Krogerus, L; Lassila, M; Nurminen, ML; Pere, AK; Vapaatalo, H | 1 |
| Basset, A; Blanc, J; Elghozi, JL; Hagège, A; Messas, E | 1 |
| Hannan, RD; Krum, H; Lim, S; See, F; Tzanidis, A; Ugoni, AM | 1 |
| Cao, H; Ke, YS; Yang, T | 1 |
| Huang, J; Xiang, Y | 1 |
| Erbaş, C; Erdine, S; Gültekin, N; Güven, O; Küçükoglu, MS; Mutlu, H; Okçün, B; Okuyan, E; Ozhan, H; Uner, S; Yigit, Z | 1 |
5 review(s) available for valsartan and Hypertrophy, Left Ventricular
| Article | Year |
|---|---|
Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Consensus; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hypertension; Hypertrophy, Left Ventricular; Middle Aged; Practice Guidelines as Topic; Primary Prevention; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Risk Factors; Saralasin; Secondary Prevention; Stroke; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2009 |
Valsartan plus hydrochlorothiazide: a review of its use since its introduction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Diuretics; Drug Combinations; Drug Costs; Drug Synergism; Humans; Hydrochlorothiazide; Hypertension; Hypertrophy, Left Ventricular; Renal Insufficiency; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2011 |
Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Cardiac Output, Low; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus; Humans; Hypertension; Hypertrophy, Left Ventricular; Kidney Failure, Chronic; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2002 |
Valsartan and the renin-angiotensin-aldosterone system: blood pressure control and beyond.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Blood Vessels; Humans; Hypertrophy, Left Ventricular; Kidney Diseases; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2000 |
Therapeutic options in minimizing left ventricular hypertrophy.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Humans; Hypertension; Hypertrophy, Left Ventricular; Receptors, Angiotensin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2000 |
25 trial(s) available for valsartan and Hypertrophy, Left Ventricular
| Article | Year |
|---|---|
Middle-Aged and Older Patients With Left Ventricular Hypertrophy: Higher Mortality With Drug Treated Systolic Blood Pressure Below 130 mm Hg.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Electrocardiography; Humans; Hypertension; Hypertrophy, Left Ventricular; Middle Aged; Valsartan | 2023 |
Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial.
Topics: Adolescent; Adult; Cardiomyopathy, Hypertrophic; Child; Female; Genetic Predisposition to Disease; Humans; Hypertrophy, Left Ventricular; Male; Valsartan; Ventricular Remodeling | 2023 |
The Design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Trial.
Topics: Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Cardiomyopathy, Hypertrophic; Child; Double-Blind Method; Genotype; Humans; Hypertrophy, Left Ventricular; Middle Aged; Mutation; Sarcomeres; Valsartan; Young Adult | 2017 |
The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Aorta; Aorta, Thoracic; Biphenyl Compounds; Blood Pressure; Double-Blind Method; Drug Combinations; Essential Hypertension; Female; Heart Failure; Humans; Hypertrophy, Left Ventricular; Imidazoles; Magnetic Resonance Angiography; Male; Medication Adherence; Middle Aged; Neprilysin; Tetrazoles; Valsartan; Vascular Stiffness; Ventricular Remodeling | 2017 |
Effects of valsartan treatment on serum ghrelin level and left ventricular mass index in patients with untreated primary hypertension.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Case-Control Studies; Echocardiography; Enzyme-Linked Immunosorbent Assay; Female; Ghrelin; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Prospective Studies; Treatment Outcome; Valsartan | 2014 |
Aortic remodelling following the treatment and regression of hypertensive left ventricular hypertrophy: a cardiovascular magnetic resonance study.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Aorta, Thoracic; Bendroflumethiazide; Dose-Response Relationship, Drug; Drug Therapy, Combination; Essential Hypertension; Female; Follow-Up Studies; Heart Ventricles; Humans; Hypertension; Hypertrophy, Left Ventricular; Imidazoles; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Sympatholytics; Treatment Outcome; Valsartan; Vascular Remodeling; Vascular Stiffness | 2015 |
Long-term treatment with valsartan improved cyclic variation of the myocardial integral backscatter signal and diastolic dysfunction in hypertensive patients: the echocardiographic assessment.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Echocardiography; Female; Fibrosis; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Myocardium; Prospective Studies; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2008 |
Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Europe; Female; Heart Ventricles; Humans; Hypertrophy, Left Ventricular; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Proportional Hazards Models; Recurrence; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Ultrasonography; United States; Valine; Valsartan; Ventricular Remodeling | 2008 |
Effects of combined therapy of Xuezhikang Capsule and Valsartan on hypertensive left ventricular hypertrophy and heart rate turbulence.
Topics: Administration, Oral; Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Capsules; Combined Modality Therapy; Drug Combinations; Drugs, Chinese Herbal; Female; Heart Rate; Humans; Hypertension; Hypertrophy, Left Ventricular; Hypolipidemic Agents; Integrative Medicine; Male; Medicine, Chinese Traditional; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
Enhanced cardiovascular protective effects of valsartan in high-risk hypertensive patients with left ventricular hypertrophy--sub-analysis of the KYOTO HEART study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Electrocardiography; Female; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Risk Factors; Tetrazoles; Valine; Valsartan | 2011 |
Effects of valsartan and amlodipine on home blood pressure and cardiovascular events in Japanese hypertensive patients: a subanalysis of the VART.
Topics: Aged; Albuminuria; Amlodipine; Angina Pectoris; Antihypertensive Agents; Asian People; Blood Pressure; Cardiovascular Diseases; Cause of Death; Creatinine; Death, Sudden; Female; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2012 |
Effects of valsartan, an angiotensin II receptor blocker, on coronary atherosclerosis in patients with acute myocardial infarction who receive an angiotensin-converting enzyme inhibitor.
Topics: Aged; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biomarkers; Blood Pressure; Captopril; Chi-Square Distribution; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Hypertrophy, Left Ventricular; Japan; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Predictive Value of Tests; Prospective Studies; Renin-Angiotensin System; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Ultrasonography, Interventional; Valine; Valsartan | 2012 |
Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Ramipril; Tetrazoles; Valine; Valsartan | 2012 |
A selective angiotensin receptor antagonist, Valsartan, produced regression of left ventricular hypertrophy associated with a reduction of arterial stiffness.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arteries; Blood Flow Velocity; Blood Pressure; Compliance; Creatinine; Double-Blind Method; Echocardiography; Elasticity; Humans; Hypertrophy, Left Ventricular; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Tetrazoles; Valine; Valsartan | 2003 |
Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy.
Topics: Amlodipine; Antihypertensive Agents; Cross-Sectional Studies; Double-Blind Method; Echocardiography; Female; Flow Cytometry; Heart Ventricles; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Monocytes; Prospective Studies; Reactive Oxygen Species; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2004 |
Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Ankle; Aorta; Blood Pressure Monitoring, Ambulatory; Drug Therapy, Combination; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Japan; Male; Middle Aged; Natriuretic Peptide, Brain; Perindopril; Prospective Studies; Pulse; Tetrazoles; Valine; Valsartan | 2005 |
Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Therapy, Combination; Electrocardiography; Female; Heart Ventricles; Hospitalization; Humans; Hypertrophy, Left Ventricular; Male; Middle Aged; Myocardial Infarction; Prognosis; Stroke Volume; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2005 |
Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Collagen Type I; Collagen Type III; Electrocardiography; Female; Follow-Up Studies; Heart Rate; Humans; Hypertension; Hypertrophy, Left Ventricular; Lipid Peroxidation; Long QT Syndrome; Male; Oxidative Stress; Prospective Studies; Tetrazoles; Valine; Valsartan | 2007 |
Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Echocardiography; Female; Heart Rate; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Renin-Angiotensin System; Stroke Volume; Tetrazoles; Valine; Valsartan | 2007 |
The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design.
Topics: Aged; Amlodipine; Angiotensin II; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Prospective Studies; Research Design; Risk Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 1998 |
Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.
Topics: Angiotensin II; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Echocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Tetrazoles; Treatment Outcome; Valine; Valsartan | 1998 |
Angiotensin II antagonism and the heart: valsartan in left ventricular hypertrophy.
Topics: Angiotensin II; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Female; Humans; Hydrochlorothiazide; Hypertrophy, Left Ventricular; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 1999 |
Angiotensin II antagonism and the heart: valsartan in left ventricular hypertrophy.
Topics: Aged; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Double-Blind Method; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 1999 |
Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Diuretics; Drug Interactions; Heart Ventricles; Humans; Hydrochlorothiazide; Hypertension; Hypertrophy, Left Ventricular; Organ Size; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Research Design; Tetrazoles; Valine; Valsartan | 1999 |
The efficacy of valsartan in essential hypertension and its effects on left ventricular hypertrophy.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Cohort Studies; Hemodynamics; Humans; Hypertension; Hypertrophy, Left Ventricular; Middle Aged; Tetrazoles; Therapeutic Equivalency; Treatment Outcome; Ultrasonography; Valine; Valsartan | 2002 |
28 other study(ies) available for valsartan and Hypertrophy, Left Ventricular
| Article | Year |
|---|---|
[Treatment of patients with heart failure and preserved ejection fraction: reliance on clinical phenotypes].
Topics: Aminobutyrates; Amyloidosis; Angiotensin Receptor Antagonists; Biphenyl Compounds; Heart Failure; Humans; Hypertrophy, Left Ventricular; Natriuretic Peptide, Brain; Phenotype; Spironolactone; Stroke Volume; Valsartan; Ventricular Function, Left | 2022 |
Protection of Sacubitril/Valsartan against Pathological Cardiac Remodeling by Inhibiting the NLRP3 Inflammasome after Relief of Pressure Overload in Mice.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Disease Models, Animal; Drug Combinations; Fibrosis; Hypertrophy, Left Ventricular; Inflammasomes; Male; Mice, Inbred C57BL; Myocardium; Neprilysin; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Protease Inhibitors; Signal Transduction; Tetrazoles; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2020 |
Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Disease Models, Animal; Drug Combinations; Fibrosis; Hemodynamics; Humans; Hypertrophy, Left Ventricular; Isoproterenol; Myocardium; Neprilysin; Protease Inhibitors; Rats, Wistar; Tetrazoles; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2019 |
AHU377+Valsartan (LCZ696) Modulates Renin-Angiotensin System (RAS) in the Cardiac of Female Spontaneously Hypertensive Rats Compared With Valsartan.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Disease Models, Animal; Drug Combinations; Female; Fibrosis; Gene Expression Regulation; Hypertension; Hypertrophy, Left Ventricular; Myocytes, Cardiac; Neprilysin; Oxidative Stress; Protease Inhibitors; Rats, Inbred SHR; Rats, Inbred WKY; Renin-Angiotensin System; Signal Transduction; Tetrazoles; Valsartan; Vasodilation; Ventricular Function, Left; Ventricular Remodeling | 2019 |
Puerarin inhibits angiotensin II-induced cardiac hypertrophy via the redox-sensitive ERK1/2, p38 and NF-κB pathways.
Topics: Administration, Oral; Angiotensin II; Animals; Antioxidants; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation; Hypertrophy, Left Ventricular; Isoflavones; Male; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Myocytes, Cardiac; NF-kappa B; Oxidation-Reduction; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Reactive Oxygen Species; Signal Transduction; Tetrazoles; Ultrasonography; Valine; Valsartan; Ventricular Remodeling | 2014 |
Valsartan improves the electrophysiological characteristics of left ventricular hypertrophic myocardium in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Heart Ventricles; Hypertrophy, Left Ventricular; Male; Myocardium; Rats; Rats, Inbred SHR; Shal Potassium Channels; Tetrazoles; Valine; Valsartan | 2014 |
Comparative effects of valsartan in combination with cilnidipine or amlodipine on cardiac remodeling and diastolic dysfunction in Dahl salt-sensitive rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Dihydropyridines; Drug Evaluation, Preclinical; Drug Therapy, Combination; Heart; Hypertension; Hypertrophy, Left Ventricular; Male; Myocytes, Cardiac; Oxidative Stress; Rats, Inbred Dahl; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2015 |
Autoantibodies against β1 receptor and AT1 receptor in type 2 diabetes patients with left ventricular dilatation.
Topics: Aged; Antihypertensive Agents; Autoantibodies; Biomarkers; Diabetes Mellitus, Type 2; Dilatation, Pathologic; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Metoprolol; Middle Aged; Predictive Value of Tests; Receptor, Angiotensin, Type 1; Receptors, Adrenergic, beta-1; Risk Factors; Sensitivity and Specificity; Tetrazoles; Valine; Valsartan | 2014 |
Tetrahydrobiopterin reverse left ventricular hypertrophy and diastolic dysfunction through the PI3K/p-Akt pathway in spontaneously hypertensive rats.
Topics: Animals; Biopterins; Blood Pressure; Body Weight; Diastole; Hypertension; Hypertrophy, Left Ventricular; Male; Organ Size; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tetrazoles; Valine; Valsartan | 2015 |
The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Collagen; Disease Models, Animal; Female; Heart Rate; Hypertrophy, Left Ventricular; Ligation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocytes, Cardiac; Ramipril; Receptor, Bradykinin B1; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2009 |
Angiotensin II receptor blocker, valsartan, increases myocardial blood volume and regresses hypertrophy in hypertensive patients.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Blood Volume; Case-Control Studies; Echocardiography, Doppler; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2009 |
Continuous positive airway pressure treatment in addition to optimal medical therapy for ventricular ectopy in a patient with heart failure and sleep-related breathing disorder.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Continuous Positive Airway Pressure; Coronary Artery Disease; Heart Failure; Humans; Hypertrophy, Left Ventricular; Male; Middle Aged; Propanolamines; Radiography; Sleep Apnea, Obstructive; Tachycardia, Ventricular; Tetrazoles; Ultrasonography; Valine; Valsartan; Ventricular Premature Complexes | 2013 |
The effect of valsartan on left ventricular myocardial functions in hypertensive patients with left ventricular hypertrophy.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomechanical Phenomena; Blood Pressure; Echocardiography, Doppler; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Myocardial Contraction; Prospective Studies; Recovery of Function; Tetrazoles; Time Factors; Treatment Outcome; Turkey; Valine; Valsartan; Ventricular Function, Left | 2012 |
Effects of angiotensin receptor blockade on haemodynamics and gene expression after myocardial infarction.
Topics: Angiotensin Receptor Antagonists; Animals; Gene Expression Regulation; Hemodynamics; Hypertrophy, Left Ventricular; Male; Myocardial Infarction; Rats; Rats, Sprague-Dawley; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan | 2002 |
Reversal of interstitial fibroblast hyperplasia via apoptosis in hypertensive rat heart with valsartan or enalapril.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Apoptosis; Enalapril; Fibroblasts; Heart Ventricles; Hyperplasia; Hypertension; Hypertrophy, Left Ventricular; In Situ Nick-End Labeling; Male; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tetrazoles; Valine; Valsartan | 2003 |
The effect of valsartan on regression of left ventricular hypertrophy in type 2 diabetic patients.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Administration Schedule; Echocardiography; Female; Glycated Hemoglobin; Heart Ventricles; Humans; Hypertrophy, Left Ventricular; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2004 |
Effects of volsartan on transmural heterogeneous changes of transient outward potassium currents in hypertrophic cardiomyocytes in rabbits.
Topics: Animals; Antihypertensive Agents; Biological Transport, Active; Female; Hypertrophy, Left Ventricular; Male; Myocytes, Cardiac; Patch-Clamp Techniques; Potassium Channels; Rabbits; Tetrazoles; Valine; Valsartan | 2004 |
Effects of glitazones on blood pressure and vascular structure in mesenteric resistance arteries and basilar artery from genetically hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Basilar Artery; Blood Pressure; Disease Models, Animal; Drug Therapy, Combination; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypertrophy, Left Ventricular; Mesenteric Arteries; Pioglitazone; Rats; Rats, Inbred SHR; Rats, Wistar; Rosiglitazone; Simvastatin; Tetrazoles; Thiazolidinediones; Tunica Media; Valine; Valsartan | 2005 |
Added VALUE of an ancillary study on ambulatory blood pressure monitoring.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Heart Rate; Humans; Hypertrophy, Left Ventricular; Randomized Controlled Trials as Topic; Reproducibility of Results; Research; Sample Size; Tetrazoles; Valine; Valsartan | 2007 |
The angiotensin type 1 receptor antagonist valsartan attenuates pathological ventricular hypertrophy induced by hyperhomocysteinemia in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Homocysteine; Hyperhomocysteinemia; Hypertrophy, Left Ventricular; Male; Organ Size; Rats; Rats, Inbred F344; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2006 |
VALIDD should not invalidate angiotensin-receptor blockers.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Myocardial Infarction; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2007 |
[Myocardial hypertrophy in rabbits with vasorenal arterial hypertension during pharmacological blockade of formation of angiotensin II and its interaction with specific receptors].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Cardiomegaly; Hypertension, Renovascular; Hypertrophy, Left Ventricular; Male; Myocardium; Rabbits; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan | 1999 |
[Morphofunctional characteristics of myocardial hypertrophy in rabbits with vasorenal arterial hypertension during pharmacological blockade of angiotensin II].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Heart Ventricles; Hypertension, Renovascular; Hypertrophy, Left Ventricular; Male; Organ Size; Rabbits; Tetrazoles; Valine; Valsartan | 1999 |
Comparison of enalapril and valsartan in cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Bradykinin; Bradykinin Receptor Antagonists; Cyclosporine; Dose-Response Relationship, Drug; Drinking; Eating; Electrolytes; Enalapril; Heart Rate; Hypertension; Hypertrophy, Left Ventricular; Kallikreins; Kidney; Kidney Diseases; Male; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptor, Bradykinin B2; Renin; Sodium, Dietary; Tetrazoles; Urination; Valine; Valsartan | 2000 |
Renin-angiotensin system contribution to cardiac hypertrophy in experimental hyperthyroidism: an echocardiographic study.
Topics: Animals; Echocardiography; Hyperthyroidism; Hypertrophy, Left Ventricular; Male; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2001 |
Combined angiotensin and endothelin receptor blockade attenuates adverse cardiac remodeling post-myocardial infarction in the rat: possible role of transforming growth factor beta(1).
Topics: Angiotensin Receptor Antagonists; Animals; Blotting, Northern; Bosentan; Collagen; Endothelin Receptor Antagonists; Female; Fibroblasts; Hemodynamics; Hypertrophy, Left Ventricular; Immunohistochemistry; Macrophages; Monocytes; Myocardial Infarction; Myocardium; Procollagen; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sulfonamides; Tetrazoles; Time Factors; Transforming Growth Factor beta; Transforming Growth Factor beta1; Valine; Valsartan; Ventricular Dysfunction, Left | 2001 |
Effect of combination of valsartan with benazepril on blood pressure and left ventricular hypertrophy in SHR.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Blood Pressure; Drug Therapy, Combination; Hypertension; Hypertrophy, Left Ventricular; Male; Random Allocation; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tetrazoles; Valine; Valsartan | 2000 |
Effect of valsartan and fosinopril on catecholamine-induced cardiac hypertrophy.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Apoptosis; Calcium-Transporting ATPases; Collagen; Female; Fosinopril; Hypertrophy, Left Ventricular; Male; Myocardium; Norepinephrine; Rats; Rats, Sprague-Dawley; Sodium-Potassium-Exchanging ATPase; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2000 |